d-Amphetamine for Cocaine Use Disorder
Trial Summary
Do I need to stop my current medications to join the trial?
The protocol does not specify if you need to stop your current medications.
What data supports the idea that d-Amphetamine for Cocaine Use Disorder is an effective drug?
The available research shows that sustained-release dexamphetamine, a form of d-Amphetamine, has shown positive effects in treating patients with cocaine use disorder. One study demonstrated that it helped reduce cocaine use in patients. Another study found that participants who took dextroamphetamine had better retention in the program and fewer positive drug tests compared to those who took a placebo. These findings suggest that d-Amphetamine can be an effective option for treating cocaine use disorder.12345
What safety data exists for d-Amphetamine in treating cocaine use disorder?
Safety data for d-Amphetamine, particularly in the form of sustained-release dexamphetamine, has been evaluated in various studies. One study focused on its use for cocaine-dependent patients with comorbid opioid dependence, indicating positive effects beyond just reducing cocaine use. Another study investigated its safety and efficacy for methamphetamine dependence, suggesting its potential safety in similar stimulant use disorders. Additionally, safety evaluations have been conducted in the context of ADHD treatment with mixed amphetamine salts, which are related formulations, providing further insights into the safety profile of amphetamines.12678
Is the drug sustained-release d-amphetamine a promising treatment for cocaine use disorder?
What is the purpose of this trial?
The objective of this protocol is to use a drug-vs-money choice task, reinforcement learning modeling and fMRI to determine the neurobehavioral and neurobiological decision-making "profile" associated with the decision to take cocaine and the reduced cocaine choice that occurs during a behavioral intervention (alternative money reinforcer) that models contingency management.
Research Team
Joshua Lile, PhD
Principal Investigator
University of Kentucky
Eligibility Criteria
This trial is for individuals who have recently used cocaine but are generally healthy. They should not have any serious physical or psychiatric diseases, and their lab results must be within normal ranges to participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in a drug-vs-money choice task using reinforcement learning modeling and fMRI to assess decision-making profiles. Each session involves 200 trials with varying monetary reinforcers.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Money
- Sustained Release d-amphetamine
Sustained Release d-amphetamine is already approved in United States, United Kingdom for the following indications:
- Attention Deficit Disorder with Hyperactivity
- Narcolepsy
- Attention Deficit Disorder with Hyperactivity
- Narcolepsy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Joshua A. Lile, Ph.D.
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator